Download PDF
Der Nuklearmediziner 2020; 43(04): 327-331
DOI: 10.1055/a-1118-4683
Uroonkologie

Die Rolle der 18F-FDG-PET/CT in der Diagnostik von gonadalen und extragonadalen Keimzelltumoren des Mannes

The role of 18F-FDG-PET/CT in male gonadal and extragonadal germ-cell cancer
Jörg Beyer
1   Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsklinik der Universität Bern, Universität Bern, Freiburgstrasse, CH-3010 Bern, Schweiz
,
Richard Cathomas
2   Departement Innere Medizin, Medizinische Onkologie und Hämatologie, Kantonsspital Graubünden, Loëstrasse 170, CH-7000 Chur, Schweiz
,
Ali Afshar-Oromieh
3   Universitätsklinik für Nuklearmedizin, Inselspital, Universitätsklinik der Universität Bern, Universität Bern, Freiburgstrasse, CH-3010 Bern, Schweiz
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Gonadale Keimzelltumoren stellen zusammen mit den seltenen extragonadalen Keimzelltumoren die häufigste Krebserkrankung von Männern zwischen der Pubertät und einem Alter von etwa 40 Jahren dar. Diagnostik, Therapie und Nachsorge wurden in klinischen Studien intensiv untersucht sowie in nationalen und internationalen Leitlinien zusammengefasst [1] [2] [3]. Die überwiegende Mehrheit Betroffener wird heutzutage geheilt. Das junge Alter sowie die hohe Heilungsaussicht zwingen mehr noch als bei anderen Erkrankungen, unnötige Strahlenbelastung zu vermeiden. Daher bleibt der Einsatz der PET/CT bei Keimzelltumoren einigen wenigen Indikationen vorbehalten.

Abstract

Gonadal germ-cell cancer is together with the rare extragonadal germ-cell cancer the most common cancer in males from puberty until the age of around 40 years. Diagnosis, treatment and follow-up has been intensively studied in clinical trials and summarized in national and international guidelines. [1] [2] [3] The young age and the high cure rate make it ever more important to avoid unnecessary radiation exposure. Therefore, the use of PET/CT remains restricted to few and highly selected indications.

Schlüsselwörter

Keimzelltumoren - Diagnostik - PET/CT - Leitlinie

Key words

germ-cell cancer - diagnosis - PET/CT - guideline


Publication History

Article published online:
30 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Albers P, Albrecht W, Algaba F. et al. Guidelines on testicular cancer: 2015 update (2020). EurUrol; 2015 68. 1054-1068 Im Internet (abgerufen am: 25.07.2020): https://uroweb.org/guideline/testicular-cancer
    PubMedGoogle Scholar
  • 2 Honecker F, Aparicio J, Berney D. et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 2018; 29: 1658-1686
    CrossrefPubMedGoogle Scholar
  • 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens, Langversion 0.1 (Konsultationsfassung), AWMF Registernummer: 043/049OL. 2018 (abgerufen am: 25.07.2020) https://www.leitlinienprogramm-onkologie.de/leitlinien/hodentumoren
    PubMedGoogle Scholar
  • 4 Schriefer P, Hartmann M, Oechsle K. et al. Positronenemissionstomographie bei Keimzelltumoren des Mannes. Urologe 2019; 58: 418-423
    CrossrefPubMedGoogle Scholar
  • 5 International Germ Cell Cancer Collaborative Group (IGCCCG). International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
    CrossrefPubMedGoogle Scholar
  • 6 Kitajima K, Nakamoto Y, Senda M. et al. Normal uptake of 18F-FDG in the testis: an assessment by PET/CT. Ann Nucl Med 2007; 21: 405-410
    CrossrefPubMedGoogle Scholar
  • 7 Lassen U, Daugaard G, Eigtved A. et al. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003; 30: 396-402
    CrossrefPubMedGoogle Scholar
  • 8 Huddart RA, O’Doherty MJ, Padhani A. et al. 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC trial TE22 — the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25: 3090-3095
    CrossrefPubMedGoogle Scholar
  • 9 Hain SF, O’Doherty MJ, Timothy AR. et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 590-594
    CrossrefPubMedGoogle Scholar
  • 10 De Wit M, Brenner W, Hartmann M. et al. [18F]-FDG–PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicenter trial. Ann Oncol 2008; 19: 1619-1623
    CrossrefPubMedGoogle Scholar
  • 11 Ambrosini V, Zucchini G, Nicolini S. et al. 18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging 2014; 41: 668-673
    CrossrefPubMedGoogle Scholar
  • 12 Cook GJ, Sohaib A, Huddart RA. et al. The role of 18F-FDG PET/CT in the management of testicular cancers. Nucl Med Commun 2015; 36: 702-708
    CrossrefPubMedGoogle Scholar
  • 13 Kollmannsberger C, Oechsle K, Dohmen BM. et al. Prospective comparison of [18F]Fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002; 94: 2353-2362
    CrossrefPubMedGoogle Scholar
  • 14 Spermon JR, De Geus-Oei LF, Kiemeney LALM. et al. The role of 18fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002; 89: 549-556
    CrossrefPubMedGoogle Scholar
  • 15 Pfannenberg AC, Oechsle K, Bokemeyer C. et al. The role of [18F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors - prospects for management. World J Urol 2004; 22: 132-139
    CrossrefPubMedGoogle Scholar
  • 16 Oechsle K, Hartmann M, Brenner W. et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomographystudygroup. J Clin Oncol 2008; 26: 5930-5935
    CrossrefPubMedGoogle Scholar
  • 17 Motzer R, Bosl G, Heelan R. et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987; 5: 1064-1070
    CrossrefPubMedGoogle Scholar
  • 18 De Santis M, Becherer A, Bokemeyer C. et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPETtrial. J Clin Oncol 2004; 22: 1034-1039
    CrossrefPubMedGoogle Scholar
  • 19 Bachner M, Loriot Y, Gross-Goupil M. et al. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23: 59-64
    CrossrefPubMedGoogle Scholar
  • 20 Horwich A, Paluchowska B, Norman A. et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8: 37-40
    CrossrefPubMedGoogle Scholar
  • 21 Cathomas R, Klingbiel D, Bernard B. et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international Global Germ Cell Cancer Group registry. J Clin Oncol 2018; 36: 3381-3387
    CrossrefPubMedGoogle Scholar
  • 22 Decoene J, Winter C, Albers P. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. Urol Oncol 2015; 33: 23.e15-23.e21
    CrossrefPubMedGoogle Scholar
  • 23 Hain SF. et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br JCancer 2000; 83: 863-869
    CrossrefPubMedGoogle Scholar